One dose of HPV vaccine could prevent most cervical cancers, studies showBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h3198 (Published 11 June 2015) Cite this as: BMJ 2015;350:h3198
- Susan Mayor
One dose of bivalent human papillomavirus (HPV) vaccine may be adequate to prevent most cases of cervical cancer, shows a study combining data from two large trials and published in Lancet Oncology1 that found similar protection against HPV infection from a single vaccination as from the current two and three dose schedules.
“Our findings question the number of HPV vaccine doses truly needed to protect the majority of women against cervical cancer and suggest that a one dose schedule should be further evaluated,” said Aimée Kreimer, co-lead author from the National Cancer Institute at the US National Institutes of Health.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial